Moreover, the latest ESC position paper on cancer treatments and cardiovascular toxicity stated that patients who develop asymptomatic LV dysfunction or HF during cancer therapy are likely to profit from the angiotensin-converting enzyme (ACE) inhibitors or ARBs and beta-blocker treatment similar to the general HF population [6]. Here, ACE is linked to cancer.